- The Institute
- Travel & Vaccines
- Alumni & Friends
Large clinical trial in five African countries yields important safety data for pyronaridine artesunate
Scientists around the world are searching for drugs to better treat malaria patiens. Great hopes are pinned on the combination drug Pyramax. In clinical trials, it proved to be highly effective and safe. However, some patients experienced temporarily elevated liver enzymes during clinical development. An international cross-institutional group of researchers therefore undertook a large-scale study in Africa on the safety, tolerability and efficacy of pyronaridine artesunate for the treatment of uncomplicated malaria under real-life conditions. The results are promising and have just been published in the journal PLOS Medicine.
Die Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V. (DTG) verleiht alle zwei Jahre den “Preis für Tropenmedizin“. Der Preis dient der Förderung jüngerer Wissenschaftler:innen und wird für besondere wissenschaftliche Leistungen auf dem Gebiet der Tropenmedizin oder der internationalen Gesundheitswissenschaften verliehen. Er ist mit 5.000 Euro dotiert und wird derzeit von der Else-Kröner-Fresenius-Stiftung finanziert.
At the first digital Summer School of the Leibniz Center Infection on the topic "Molecular biology of pathogens", PhD students from the Bernhard Nocht Institute for Tropical Medicine (BNITM), the Research Center Borstel - Leibniz Lung Center (FZB) and the Leibniz Institute for Experimental Virology (HPI) came together for a two-day digital meeting to exchange ideas on current topics in infection biology.
Cross-institutional research group adds important molecular biology puzzle piece to explanation
Malaria is known to be a severe and fatal disease in Africa especially in children under five. Due to the much smaller number of cases, the causes of severe disease in adults have so far been insufficiently researched. A cross-institutional research group led by Dr. Anna Bachmann in the Department of Cellular Parasitology at the Bernhard Nocht Institute for Tropical Medicine (BNITM) has now been able to analyse the malaria cases of 32 adults who suffered from varying degrees of malaria. The researchers found important differences between children and adults in the binding of malaria-infected red blood cells to the blood vessel walls. The results were recently published in the scientific journal eLife.
Dr. Sophie Duraffour from the Department of Virology at the Bernhard Nocht Institute for Tropical Medicine (BNITM) receives the "Clinical Research" award of the GlaxoSmithKline Foundation. The prize is endowed with 10,000 euros. It is awarded in recognition of outstanding scientific work.
Worm infections are among the most common tropical diseases worldwide. Parasitic worms are such successful infectious agents partly because they are able to weaken the immune response of their host. But the host also knows what to do: It reacts with a complex interplay of different messenger substances of the immune system.
BNITM-Work group Tobias Spielmann receives ERC Advanced Grant
Hamburg, Germany, April 22, 2021 – Dr. Tobias Spielmann, head of the research group "Malaria" in the section Molecular Biology and Immunology at the Bernhard Nocht Institute for Tropical Medicine (BNITM), has been awarded an ERC Advanced Grant of almost 2.4 million euros by the European Research Council (ERC). With this highly endowed funding, the research group will investigate specific forms of drug resistance in malaria parasites over the next five years.
Background and expert service
In 2000, the World Health Organization (WHO) established the World Malaria Day as an annual international day of action. Its purpose is to remind that more than three billion people in the world are at risk from malaria. The WHO and other organizations are working to roll back this infectious disease at great financial and logistical expense. This has led to a reduction in new cases in recent years. However, for the first-time last year, the WHO recorded an increase to around 230 million malaria cases worldwide, of which more than 400,000 were fatal. Children under the age of five in Africa account for more than two-thirds of the deaths. Our interview partners for journalists can be found below.
Joint major project in the fight against SARS-CoV-2
Hamburg. At the high-brilliance X-ray light source PETRA III of the German Electron Synchrotron (DESY), a research team in which the Bernhard Nocht Institute for Tropical Medicine (BNITM) is also active has identified several candidates for active agents against the coronavirus SARS-CoV-2. The promising drug candidates bind to an important protein of the virus and could thus be the basis for a drug against COVID-19.
BNITM-teams assisted in testing and sequencing patient samples
Following the request for assistance from the Ministry of Health of Guinea, the Bernhard Nocht Institute for Tropical Medicine (BNITM) sent teams to support Guinea in setting up in-country sequencing with the Oxford Nanopore MinION and to strengthen diagnostic capacity needs. The mission took place within the framework of the WHO Global outbreak alert and response network (GOARN) and the Global Health Protection Programme (GHPP) of the Federal Ministry of Health.